

#### LOCAL OPERATING PROCEDURE

## **CLINICAL POLICIES, PROCEDURES & GUIDELINES**

Approved by Quality & Patient Safety Committee 20 November 2014

# TERBUTALINE (BRICANYL) – SUBCUTANEOUS INJECTION FOR UTERINE HYPERTONUS OR ACUTE FETAL DISTRESS

**Presentation:** Terbutaline Sulphate (Bricanyl) 0.5mg in 1 ml

**General:** Terbutaline is a beta 2 agonist with similar properties to salbutamol

(Ventolin) however it can be given subcutaneously.

**Indications:** 1) Acute fetal distress where uterine relaxation is required.

2) Uterine hypertonus related to induction of labour with oxytocics

or prostaglandins.

**Administration:** i) The patient should positioned on their side and any oxytocin

intravenous infusion ceased prior to consideration of

terbutaline for uterine relaxation.

ii) IV salbutamol 200 microgram IV infusion has a similar action.

**Contraindications:** Imminent delivery, unexplained vaginal bleeding.

**Dosage:** 0.25mg terbutaline (0.5mL) subcutaneously. This may be

administered by medical or nursing staff pursuant to standing orders.

**Side-effects:** Maternal and fetal tachycardia, maternal headache.

### REFERENCE:

Culier R, Hofmeyer G. Tocolytics for Suspected Intrapartum Fetal distress. Cochrane Database Systemic of Reviews 2000 (Issue No 3).

RISK RATING: Low- review in 5 years

### **REVISION & APPROVAL HISTORY**

Reviewed and Endorsed Therapeutic & Drug Utilisation Committee 14/10/14 Approved Quality & Patient Safety Committee 15/7/10 Reviewed and Endorsed Therapeutic & Drug Utilisation Committee 12/4/10 Approved Quality Council 17/2/03

FOR REVIEW: OCTOBER 2019